Aled Williams
Directeur/Membre du Conseil chez DESTINY PHARMA PLC
Fortune : 11 113 $ au 30/04/2024
Relations actives
| Nom | Sexe | Age | Sociétés liées | Collaboration |
|---|---|---|---|---|
| William Love | M | 62 | 28 ans | |
| Debra Stephanie Barker | M | 61 | 4 ans | |
| Shaun Claydon | M | 56 | 6 ans | |
| Anthony Rudd | M | 76 | 13 ans | |
| Nigel Brooksby | M | - | 2 ans | |
| Christopher Tovey | M | 59 | 1 ans | |
| Lisa Olson | M | 63 |
Enthera Srl
 Enthera Srl BiotechnologyHealth Technology Enthera Srl develops therapeutic solutions to treat diabetes. The company was founded in 1985 by in October 2016 by Maria Gabriella Camboni, Paolo Fiorina and Francesca D'Addio and is headquartered in Milan, Italy. | - |
| James Stearns | M | - | 2 ans | |
| William Rhys-Williams | M | - | 26 ans | |
| Jim Lees | M | - | 7 ans |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
| Nom | Sexe | Age | Sociétés liées | Collaboration |
|---|---|---|---|---|
| Nick Rodgers | M | 65 | 5 ans | |
| Neil Clark | M | 62 | 6 ans | |
| Huai Zheng Peng | M | 62 | 5 ans | |
| Stephanie Bewick | M | - | 2 ans | |
| Behrad Derakhshan | M | 44 |
VectivBio AG
 VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 1 ans |
Statistiques
| Pays | Relations | % du total |
|---|---|---|
| Royaume-Uni | 13 | 86,67% |
| Suisse | 1 | 6,67% |
| Italie | 1 | 6,67% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Aled Williams
- Réseau Personnel
